136 related articles for article (PubMed ID: 18635195)
1. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody.
Covaceuszach S; Cassetta A; Konarev PV; Gonfloni S; Rudolph R; Svergun DI; Lamba D; Cattaneo A
J Mol Biol; 2008 Sep; 381(4):881-96. PubMed ID: 18635195
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic structural disorder of mouse proNGF.
Paoletti F; Covaceuszach S; Konarev PV; Gonfloni S; Malerba F; Schwarz E; Svergun DI; Cattaneo A; Lamba D
Proteins; 2009 Jun; 75(4):990-1009. PubMed ID: 19089979
[TBL] [Abstract][Full Text] [Related]
4. Purification, crystallization, X-ray diffraction analysis and phasing of a Fab fragment of monoclonal neuroantibody alphaD11 against nerve growth factor.
Covaceuszach S; Cassetta A; Cattaneo A; Lamba D
Acta Crystallogr D Biol Crystallogr; 2004 Jul; 60(Pt 7):1323-7. PubMed ID: 15213405
[TBL] [Abstract][Full Text] [Related]
5. Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.
Covaceuszach S; Marinelli S; Krastanova I; Ugolini G; Pavone F; Lamba D; Cattaneo A
PLoS One; 2012; 7(3):e32212. PubMed ID: 22403636
[TBL] [Abstract][Full Text] [Related]
6. Nerve growth factor (NGF) influences differentiation and proliferation of myogenic cells in vitro via TrKA.
Rende M; Brizi E; Conner J; Treves S; Censier K; Provenzano C; Taglialatela G; Sanna PP; Donato R
Int J Dev Neurosci; 2000 Dec; 18(8):869-85. PubMed ID: 11154856
[TBL] [Abstract][Full Text] [Related]
7. The conundrum of the high-affinity NGF binding site formation unveiled?
Covaceuszach S; Konarev PV; Cassetta A; Paoletti F; Svergun DI; Lamba D; Cattaneo A
Biophys J; 2015 Feb; 108(3):687-97. PubMed ID: 25650935
[TBL] [Abstract][Full Text] [Related]
8. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors.
Wehrman T; He X; Raab B; Dukipatti A; Blau H; Garcia KC
Neuron; 2007 Jan; 53(1):25-38. PubMed ID: 17196528
[TBL] [Abstract][Full Text] [Related]
9. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis.
Hongo JS; Laramee GR; Urfer R; Shelton DL; Restivo T; Sadick M; Galloway A; Chu H; Winslow JW
Hybridoma; 2000 Jun; 19(3):215-27. PubMed ID: 10952410
[TBL] [Abstract][Full Text] [Related]
10. Nerve growth factor: structure and function.
Wiesmann C; de Vos AM
Cell Mol Life Sci; 2001 May; 58(5-6):748-59. PubMed ID: 11437236
[TBL] [Abstract][Full Text] [Related]
11. Structural model for p75(NTR)-TrkA intracellular domain interaction: a combined FRET and bioinformatics study.
Iacaruso MF; Galli S; Martà M; Villalta JI; Estrin DA; Jares-Erijman EA; Pietrasanta LI
J Mol Biol; 2011 Dec; 414(5):681-98. PubMed ID: 21978666
[TBL] [Abstract][Full Text] [Related]
12. Swedish Nerve Growth Factor Mutation (NGF
Sung K; Ferrari LF; Yang W; Chung C; Zhao X; Gu Y; Lin S; Zhang K; Cui B; Pearn ML; Maloney MT; Mobley WC; Levine JD; Wu C
J Neurosci; 2018 Apr; 38(14):3394-3413. PubMed ID: 29483280
[TBL] [Abstract][Full Text] [Related]
13. Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2-carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA.
Colquhoun A; Lawrance GM; Shamovsky IL; Riopelle RJ; Ross GM
J Pharmacol Exp Ther; 2004 Aug; 310(2):505-11. PubMed ID: 15051797
[TBL] [Abstract][Full Text] [Related]
14. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75.
He XL; Garcia KC
Science; 2004 May; 304(5672):870-5. PubMed ID: 15131306
[TBL] [Abstract][Full Text] [Related]
15. The Copper(II)-Assisted Connection between NGF and BDNF by Means of Nerve Growth Factor-Mimicking Short Peptides.
Naletova I; Satriano C; Pietropaolo A; Gianì F; Pandini G; Triaca V; Amadoro G; Latina V; Calissano P; Travaglia A; Nicoletti VG; La Mendola D; Rizzarelli E
Cells; 2019 Apr; 8(4):. PubMed ID: 30939824
[TBL] [Abstract][Full Text] [Related]
16. Structural biology. The p75 NGF receptor exposed.
Zampieri N; Chao MV
Science; 2004 May; 304(5672):833-4. PubMed ID: 15131296
[No Abstract] [Full Text] [Related]
17. Purification, crystallization and preliminary X-ray analysis of the Fab fragment from MNAC13, a novel antagonistic anti-tyrosine kinase A receptor monoclonal antibody.
Covaceuszach S; Cattaneo A; Lamba D
Acta Crystallogr D Biol Crystallogr; 2001 Sep; 57(Pt 9):1307-9. PubMed ID: 11526327
[TBL] [Abstract][Full Text] [Related]
18. The inorganic perspective of nerve growth factor: interactions of Cu2+ and Zn2+ with the N-terminus fragment of nerve growth factor encompassing the recognition domain of the TrkA receptor.
Travaglia A; Arena G; Fattorusso R; Isernia C; La Mendola D; Malgieri G; Nicoletti VG; Rizzarelli E
Chemistry; 2011 Mar; 17(13):3726-38. PubMed ID: 21394800
[TBL] [Abstract][Full Text] [Related]
19. NGF ligand alters NGF signaling via p75(NTR) and trkA.
Niederhauser O; Mangold M; Schubenel R; Kusznir EA; Schmidt D; Hertel C
J Neurosci Res; 2000 Aug; 61(3):263-72. PubMed ID: 10900073
[TBL] [Abstract][Full Text] [Related]
20. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors.
Abdiche YN; Malashock DS; Pons J
Protein Sci; 2008 Aug; 17(8):1326-35. PubMed ID: 18505735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
